🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children

RecruitingPhase 2Ages 1 Year - 2 YearsAllUniversity of Virginia
NCT07451171 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Positive glucose hydrogen breath test (GHBT) * Weight-for-age Z score \> -1 * Length-for-age Z score \> -1 Exclusion Criteria: * Presence of known chronic or congenital illness, including developmental delay * Presence of acute gastrointestinal illness in the preceding 14 days * Antibiotic use in the preceding 14 days * Previous adverse reaction to any of the three study medications or other drugs in the same antibiotic classes * Sibling previously enrolled in this study
💊

What it tests

  • Trimethoprim-sulfamethoxazole (TMP/SMX)
  • Metronidazole
  • Amoxicillin-Clavulanate (4:1 formulation)
📍

Where

1 site
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Dhaka, Bangladesh
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy